Adia Med, Inc. (ADIA) stock
Close on Oct 19, 2026Market cap $20.98MP/E –Yield –
Adia Med, Inc. grew revenue 10879.7% to $700.51K over fiscal 2025. Free cash flow was -$192.43K. At the latest close the market valued the company at $20.98M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $20.98M
- P/E ratio
- –
- Price to sales
- 29.95
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.92%
Fundamentals
- Revenue
- $700.51K
- Net income
- -$395.46K
- EPS, diluted
- $0.00
- Free cash flow
- -$192.43K
- Book value per share
- -$0.00
- Diluted shares
- 161M
Trading
- Previous close
- $0.14
- Open
- $0.13
- Day's range
- $0.13 – $0.13
- Volume
- 2,600
- Average volume (20 days)
- 24,230
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADIA | S&P 500 | Difference | ADIA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.6% | +0.6% | +3.0 pts | ||
| 3 months | +13.0% | +3.4% | +9.7 pts | ||
| Year to date | +66.7% | +13.3% | +53.4 pts | ||
| 1 year | +212.5% | +16.6% | +195.9 pts | ||
| 3 years | +490.9% | +86.4% | +404.5 pts | +80.8% | +23.1% |
| 5 years | +6400.0% | +81.9% | +6318.1 pts | +130.5% | +12.7% |
| 10 years | +1344.4% | +318.9% | +1025.6 pts | +30.6% | +15.4% |
Three years at a glance
Fiscal years 2023 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Adia Med filed with the SEC as exhibits to Form 8-K or 6-K
About Adia Med
Medicinal Chemicals & Botanical Products
ADIA Nutrition, Inc. is a biotechnology and healthcare company specializing in regenerative medicine and dietary supplements. The company operates primarily through its Adia Med and Adia Labs divisions. Adia Med delivers regenerative medical therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and Umbilical Cord Stem Cell procedures, to patients through specialized clinical locations. Adia Labs procures and distributes biologic products, including its proprietary AdiaVita and AdiaLink offerings, to healthcare facilities and research professionals. Beyond its biologics business, the enterprise distributes organic dietary supplements directly to consumers through an equity interest in a nutrition company. The firm serves patients, medical practitioners, researchers, and retail wellness consumers.
Company profile, executives and historyAdia Med stock: common questions
What is Adia Med's stock price?
ADIA closed at $0.13 on Oct 19, 2026, down 7.14% on the day.
What is Adia Med's market cap?
Adia Med was worth $20.98M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ADIA's P/E ratio?
Adia Med lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Adia Med make?
Adia Med reported revenue of $700.51K for fiscal 2025, up 10879.7% from a year earlier.
Does Adia Med pay a dividend?
No. Adia Med has not paid a cash dividend over the last twelve months.
How has ADIA stock performed over the past year?
Including dividends, ADIA returned +212.5% over the past year, against +16.6% for the S&P 500.
Who are Adia Med's competitors?
Companies most similar to Adia Med by business, industry and size include RAJAF, LGVN, PROK, PLUR, GDTC.
See a number that looks wrong?